Investor Presentaiton
11
Commercial execution and innovation
Diabetes care
Despite uptake of GLP-1s, few patients are treated in
International Operations
GLP-1 increases as part of
the diabetes value market
5%
14%
OzempicⓇ sales in IO in million DKK
8,855
Novo NordiskⓇ
A fraction of diabetes prescriptions are GLP-1s
(% of total diabetes market)
32%
19%
14%
8%
10%
6%
39
2%
3%
1%
1%
2021
2018
2021
Total NAO Total IO
EMEA
ROW
Region
China
GLP-1 value share
GLP-1 volume share
2016
Insulin
GLP-1
OADS
ROW: Rest of world; EMEA: Europe, Middle East and Africa; Region China includes Mainland China, Taiwan and Hong Kong; OAD: Oral anti-diabetes medicine; IO: International Operations; NAO: North America Operations
Source: IQVIA December 2021
CMD22
CAPITAL MARKETS DAYView entire presentation